The Efficiency and Toxicity OfAnlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study

被引：1
|
作者：
Chen, Xi [1 ]
Wei, Xinyu [1 ]
Yao, Peizhuo [1 ]
Liu, Yanbin [1 ]
Guan, Haitao [2 ]
Kang, Huafeng [2 ]
Liu, Di [2 ]
Diao, Yan [2 ]
Ma, Xiaobin [2 ]
Min, Weili [2 ]
Shan, Changyou [2 ]
Zhao, Yang [2 ]
Zhao, Fang [2 ]
Chen, Yuanyuan [3 ]
Xiao, Dong [4 ]
She, Qing [3 ]
Liu, Youhuai [3 ]
Zhang, Yinbin [2 ]
Zhang, Shuqun [2 ]
机构：
[1] Xi An Jiao Tong Univ, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, 157,West 5th Rd, Xian 710004, Shaanxi, Peoples R China
[3] Baoji Cent Hosp Shaanxi Prov, Baoji, Shaanxi, Peoples R China
[4] 3201 Hosp Hanzhong City, Hanzhong, Shaanxi, Peoples R China
来源：
CLINICAL BREAST CANCER | 2024年 / 24卷 / 04期
关键词：
1ST-LINE TREATMENT; BEVACIZUMAB; PACLITAXEL; INHIBITOR; EFFICACY; CHEMOTHERAPY; KINASE; SAFETY; TRIAL;
D O I：
10.1016/j.clbc.2024.01.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 202
页数：8
相关论文
共 50 条
  • [21] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Wang, Chengzheng
    Liu, Zhenzhen
    Chen, Xiuchun
    Qiao, Jianghua
    Lu, Zhenduo
    Li, Lianfang
    Sun, Xianfu
    Zhang, Chongjian
    Yue, Xiayu
    Xia, Qingxin
    Zhang, He
    Yan, Min
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [22] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
    Chengzheng Wang
    Zhenzhen Liu
    Xiuchun Chen
    Jianghua Qiao
    Zhenduo Lu
    Lianfang Li
    Xianfu Sun
    Chongjian Zhang
    Xiayu Yue
    Qingxin Xia
    He Zhang
    Min Yan
    Nature Communications, 14 (1)
  • [23] Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
    Earl, Helena M.
    Hiller, Louise
    Dunn, Janet A.
    Blenkinsop, Clare
    Grybowicz, Louise
    Vallier, Anne-Laure
    Abraham, Jean
    Thomas, Jeremy
    Provenzano, Elena
    Hughes-Davies, Luke
    Gounaris, Ioannis
    McAdam, Karen
    Chan, Stephen
    Ahmad, Rizvana
    Hickish, Tamas
    Houston, Stephen
    Rea, Daniel
    Bartlett, John
    Caldas, Carlos
    Cameron, David A.
    Hayward, Larry
    LANCET ONCOLOGY, 2015, 16 (06): : 656 - 666
  • [24] Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology
    Fontaine, C.
    Cappoen, N.
    Renard, V.
    Vuylsteke, P.
    Van den Bulck, H.
    Glorieux, P.
    de Roodenbeke, D. t'Kint
    Dopchie, C.
    Decoster, L.
    Vanacker, L.
    De Greve, J.
    Awada, A.
    Wildiers, H.
    CANCER RESEARCH, 2017, 77
  • [25] Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/trastuzumab) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
    Gao, Hong-Fei
    Wu, Zhiyong
    Lin, Ying
    Song, Xiangyang
    Cao, Yin
    Liu, Zhenzhen
    Chen, Qian-Jun
    Zhang, Liulu
    Yang, Ci-Qiu
    Yang, Mei
    Zhu, Teng
    Li, Jieqing
    Ji, Fei
    Cheng, Min-Yi
    Wang, Kun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] MetaPHER: A phase IIlb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab, in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer
    Kummel, S.
    Crepelle-Flechais, A.
    Schlegel, M.
    Hillenbach, C.
    Swat, A.
    Franz, M.
    Girase, P.
    Schneider, A.
    Heinzmann, D.
    Shing, M.
    CANCER RESEARCH, 2016, 76
  • [27] KN026 in combination with docetaxel as neoadjuvant treatment for HER2+early or locally advanced breast cancer (BC): A single-arm, multicenter, phase II study
    Ma, L.
    Yang, B.
    Zhang, M.
    Wang, K.
    Chen, Y.
    Fan, Z.
    Zhang, J.
    Xia, B.
    Wu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S282 - S282
  • [28] Liposome-encapsulated doxorubicin plus cyclophosphamide followed by trastuzumab plus docetaxel as neoadjuvant therapy for HER2-positive breast cancer (BC): A multicenter single-arm phase II study
    Saracchini, Silvana
    Foltran, Luisa
    Sulfaro, Sandro
    Tuccia, Fausto
    Del Conte, Alessandro
    Bertolla, Manuella
    Bassini, Anna
    Micheli, Elvia
    Manente, Stefania
    Gusso, Giuseppina
    Baresic, Tania
    Tumoio, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [29] Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
    Liu, Yin
    Fan, Lei
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    ONCOLOGIST, 2023, 28 (01): : 86 - +
  • [30] Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study
    Marty, Francisco M.
    Man, Choy Y.
    van der Horst, Charles
    Francois, Bruno
    Garot, Denis
    Manez, Rafael
    Thamlikitkul, Visanu
    Lorente, Jose A.
    Alvarez-Lerma, Francisco
    Brealey, David
    Zhao, Henry H.
    Weller, Steve
    Yates, Phillip J.
    Peppercorn, Amanda F.
    JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (04): : 542 - 550
12345